Synapse

← Cancer Treatment and Research Communications

Papers in Cancer Treatment and Research Communications

Page 8 · newest first

  1. Targeted therapy for non-small cell lung cancer (NSCLC) in a real-world setting: A single practice experience.Cancer Treatment and Research Communications · 2025
  2. 3-month postoperative efficacy evaluation of CT-guided 125I seed implantation treatment for intracranial tumors: A double-center retrospective analysisCancer Treatment and Research Communications · 2025
  3. Investigating the quality of sexual function in women with genital cancers: A structural equation analysis approachCancer Treatment and Research Communications · 2025
  4. Partial nephrectomy Vs. Percutaneous thermal ablation of small renal massesCancer Treatment and Research Communications · 2025
  5. Harnessing PUMA's lethal potential: BCL-2 family dynamics and novel strategies to combat cancer recurrenceCancer Treatment and Research Communications · 2025
  6. DNA nanostructures as promising anticancer agents: a reviewCancer Treatment and Research Communications · 2025
  7. Artificial intelligence in Glioblastoma Diagnostics: Integrating MRI, histopathology, and molecular profilingCancer Treatment and Research Communications · 2025
  8. Effectiveness of problem-solving skills training on the self-efficacy and self-concept of the adolescent with cancerCancer Treatment and Research Communications · 2025
  9. Targeting the phosphatidylinositol-3-kinase (PI3K) and mitogen activated protein kinase (MAPK) signalling pathways to enhance chemoradiotherapy in locally advanced rectal cancerCancer Treatment and Research Communications · 2025
  10. Effect of hypoxia on extracellular vesicles in malignant and non-malignant conditionsCancer Treatment and Research Communications · 2025
  11. Development of anti-cancer medicines in the current eraCancer Treatment and Research Communications · 2025
  12. Study protocol of an open-label prospective phase II study of Durvalumab plus Carboplatin and Etoposide in advanced large cell neuroendocrine carcinoma of the lung (LOGIK2401: NECTAR study)Cancer Treatment and Research Communications · 2025
  13. First-line durvalumab plus platinum–etoposide in Japanese patients with extensive-stage small-cell lung cancerCancer Treatment and Research Communications · 2025
  14. PI3K inhibitors: Efficacy in diverse cancer formsCancer Treatment and Research Communications · 2025
  15. Advances in the management of lung & gastro-intestinal cancers: clinical studies review from ASCO 2022/2023 annual meetingsCancer Treatment and Research Communications · 2025
  16. Direct-to-patient research: Opportunity brings challengesCancer Treatment and Research Communications · 2025
  17. Durvalumab consolidation after chemoradiotherapy in unresectable stage III non–small cell lung cancer: A real-world experience from the Australian subset of PACIFIC-RCancer Treatment and Research Communications · 2025
  18. Establishment and characterization of patient-derived xenograft of scrotal Paget's diseaseCancer Treatment and Research Communications · 2025
  19. Enhancing T cell infiltration in glioblastoma: a review article on challenges and therapeutic strategiesCancer Treatment and Research Communications · 2025
  20. Evaluation of recurrence and survival in multifocal versus unifocal breast cancer patients at a tertiary center: A case-control studyCancer Treatment and Research Communications · 2025
  21. Paclitaxel resistance in breast cancer: Current challenges and recent advanced therapeutic strategiesCancer Treatment and Research Communications · 2025
  22. Artificial intelligence-based pharmacological approach in non-small cell lung cancer in the precision medicine eraCancer Treatment and Research Communications · 2025
  23. Epidemiological description of genetic alterations and prognosis in Mexican patients with melanoma: a retrospective cohortCancer Treatment and Research Communications · 2025
  24. Oxaliplatin and/or gemcitabine vs. FOLFIRINOX in first-line Advanced pancreatic adenocarcinoma: Real-world efficacy and safety data of moroccan patientsCancer Treatment and Research Communications · 2025
  25. Influence of histopathological changes after neoadjuvant chemotherapy on the survival of breast cancer patientsCancer Treatment and Research Communications · 2025
  26. Comprehensive review on outcomes from Phase 3 clinical trials of drugs in multiple myelomaCancer Treatment and Research Communications · 2025
  27. Uncovering the transcriptomic basis of endoxifen resistance in ER+ breast cancer cells: Insights from bioinformatics analysisCancer Treatment and Research Communications · 2025
  28. A novel 9-gene classifier for predicting distant metastasis of soft-tissue sarcoma and multiple malignanciesCancer Treatment and Research Communications · 2025
  29. Effectiveness and safety of Atezolizumab in patients with locally-advanced or metastatic non-small cell lung cancer after prior chemotherapy under real-life conditions in Germany: The Non-interventional Study HYPERIONCancer Treatment and Research Communications · 2025
  30. Epidermal growth factor receptor specific immunotherapy for SHH medulloblastoma tested in an in vitro blood-brain barrier-modelCancer Treatment and Research Communications · 2025
  31. Retrospective database analysis to assess treatment patterns, clinical outcomes, and healthcare resource utilization in metastatic or recurrent HER2-positive breast cancer in AlbertaCancer Treatment and Research Communications · 2025
  32. Accuracy of Image-guided Tru-cut biopsy in the diagnosis of breast tumorsCancer Treatment and Research Communications · 2025
  33. Improving fertility preservation for male cancer patients: A scoping review of barriers and facilitatorsCancer Treatment and Research Communications · 2025
  34. Oncological outcomes and locoregional recurrence after fluorescence guided surgery for axillary staging in early breast cancer: A single UK center experienceCancer Treatment and Research Communications · 2025
  35. Neoadjuvant FOLFOXIRI for locally advanced rectal cancer: A retrospective analysis focusing on long-term anal preservationCancer Treatment and Research Communications · 2025
  36. Management of immune-related adverse events under PD-1/PD-L1 inhibitors: Insights from a Moroccan real-world experienceCancer Treatment and Research Communications · 2025
  37. Impact of Using Intraoperative Nomograms with One-Step Nucleic Acid Amplification to Omit Axillary Lymph Node Dissection in Patients with Breast Cancer Who Underwent MastectomyCancer Treatment and Research Communications · 2025
  38. Unlocking the code: The role of molecular and genetic profiling in revolutionizing glioblastoma treatmentCancer Treatment and Research Communications · 2025
  39. HOXB and HOXD genes contribute to the carcinogenic processes in glioblastoma: evidence form a bioinformatics analysisCancer Treatment and Research Communications · 2025
  40. Factors influencing smoking cessation in Lebanese patients with bladder cancer: A cross sectional studyCancer Treatment and Research Communications · 2025
  41. Efficacy and safety of zanubrutinib combined with chimeric antigen receptor T-cell therapy targeting CD19 in refractory or relapsed diffuse large B cell lymphoma: A retrospective analysisCancer Treatment and Research Communications · 2025
  42. Neuro-oncological research output in the Middle East: A scoping reviewCancer Treatment and Research Communications · 2025
  43. Targeting lipid metabolism to overcome tamoxifen resistance in breast cancer: Evaluating the synergistic therapeutic potential of quercetinCancer Treatment and Research Communications · 2025
  44. Real-world treatment patterns of patients with EGFR exon 20 insertion–mutated advanced NSCLC treated with amivantamab or mobocertinib after platinum-based chemotherapy: A multi-database cohort studyCancer Treatment and Research Communications · 2025
  45. Bacterial oncolytic therapy as a novel approach for cancer treatment in humansCancer Treatment and Research Communications · 2025
  46. The impact of multiple neoadjuvant chemotherapy cycles in patients with advanced epithelial ovarian cancer: A single center experienceCancer Treatment and Research Communications · 2025
  47. A retrospective study to investigate the prevalence and describe the clinicopathological characteristics, treatments, and outcomes of HER2-low Breast Cancer in TaiwanCancer Treatment and Research Communications · 2025
  48. Assessing the pathogenicity of a variant of uncertain significance in the ALK gene in right-sided colon polyposisCancer Treatment and Research Communications · 2025
  49. Second-line therapy adjustment for advanced pancreatic cancer using circulating tumor cells: Preliminary resultsCancer Treatment and Research Communications · 2025
  50. Clinical significance of concurrent TP53 mutations in KRAS-mutant invasive mucinous adenocarcinoma patients undergoing curative-intent lung surgeryCancer Treatment and Research Communications · 2025